Positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer

Ads

You May Also Like

Medigene announces outlicensing of AAVLP technology

2A Pharma AB to continue development of AAVLP based vaccines             Martinsried/Munich, 20 December 2016. Medigene ...

Six Fertility Centers of Illinois Physicians Named 2016 Top Doctors

CHICAGO, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Six Fertility Centers of Illinois (FCI) physicians ...